Get started

Stockpicks

VOD Vodafone and MSFT Microsoft Partnership After reaching its May 2010 level, I believe Vodafone (VOD) stock is primed for a rally! Its metrics are outstanding: Forward Dividend & Yield: 0.97 (11.09%) and PE Ratio (TTM): 2.13. Additionally, there is a significant partnership with Microsoft (MSFT): Microsoft initiated a 10-year strategic partnership with Vodafone (VOD) aimed at leveraging their respective strengths to create new digital and financial services tailored for businesses, especially small and medium-sized enterprises (SMEs) across Europe and Africa. The collaboration involves the utilization of Microsoft's generative artificial intelligence (AI) to enhance Vodafone's customer experience, with the goal of delivering a more personalized and differentiated service through various channels. The partnership seeks to expand and improve Vodafone's managed Internet of Things (IoT) connectivity platform, aiming to scale up the telecommunication company's IoT platform by connecting more devices, vehicles, and machines. I`m considering the $9 strike price at the money Call for February 16, or the $10 call for March 15.
NASDAQ:VODLong
by TopgOptions
Value Investing: STOCKS to watch in 2024Hi Traders, Investors and Speculators of Charts📈📉 Welcome to 2024🥂🥳 After great feedback from the altcoin list, I'll be doing a series on top stocks to watch for 2024, all in one post for your convenience! Stocks I'll focus on include: 📢 Undervalued stocks 📢 Stocks with great upside potential 📢 New stocks to watch I'll keep adding/updating one by one to the bottom of this post, so make sure you bookmark and follow! 1) AMEX:PSIL The AdvisorShares Psychedelics ETF (NYSE ticker: PSIL) invests in the emerging psychedelic drugs sector, offering exposure to those biotechnology, pharmaceutical and life sciences companies we see as leading the way in this nascent industry.
AMEX:PSILLong
by Crypto-Check-
2
CYBIN - The Mushroom Long Term Play Amidst my re-evaluation of markets, divestment from crypto, and future planning, I'm slowly building a long term position in CYBIN. As a therapist who also happens to be a fan of psychedelics, this one fits me well. I think it can continue to flounder around, and perhaps test some even lower levels. Just looking for optimal entry points now, and managed to scoop some up the other day at $0.50. Over the next 10 years, I think the psychedelic mushroom industry will be an interesting place for growth. Screw tech. Mushrooms all the way! And not just the magic ones. I'll be on the lookout for other companies as well, and should probably devote some more time to research. I placed some theoretical targets for this, since the company is currently valued just under $100M. I think $3 Billion is fairly conservative, hence the $15 target. This is meant for speculation only, and not as financial advice. -Victor Cobra
AMEX:CYBNLong
by VictorCobra
4
HBS.N0000 - Falling wedge patternFalling wedge pattern and bullish divergence in daily chart. Wait for a pullback and target around 20-25. Disclaimer: The information and analysis provided in this publication are for educational purposes only and should not be construed as financial advice or recommendations to buy, sell, or hold any securities. The author and TradingView are not responsible for any investment decisions made based on the content presented herein. Always consult a financial professional before making any investment decisions.
CSELK:HBS.N0000Long
by rukshan2102
Why Boiron Stock Deserves Attention. Stock to buyAre you a believer in the power of natural remedies and alternative medicine? If so, get ready to discover a hidden gem in healthcare stock investments – Boiron stock. Homeopathy has been gaining traction as an effective and holistic approach to healing for centuries, and now it’s time to uncover its potential from an investor’s perspective. Join me as I delve into why Boiron stock deserves your attention, unravelling the mysteries behind this ancient practice and exploring the promising future. Get ready to be captivated by the untapped opportunities waiting within this fascinating industry! The stock has reached a solid monthly demand imbalance at €39 per share. The price of this French stock has already started to rally since the imbalance took control last 23rd October 2023. Watch the video below for a complete analysis of this French stock.
EURONEXT:BOILong
by AlfonsoMoreno
SciPlay | SCPLIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in SciPlay. While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation especially if its growing. If a company can keep growing earnings per share long enough, its share price should eventually follow. That makes EPS growth an attractive quality for any company. We can see that in the last three years SciPlay grew its EPS by 13% per year. That's a good rate of growth, if it can be sustained. Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. While SciPlay did well to grow revenue over the last year, EBIT margins were dampened at the same time. If EBIT margins are able to stay balanced and this revenue growth continues, then we should see brighter days ahead. You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for SciPlay's future profits. It's a good habit to check into a company's remuneration policies to ensure that the CEO and management team aren't putting their own interests before that of the shareholder with excessive salary packages. Our analysis has discovered that the median total compensation for the CEOs of companies like SciPlay with market caps between US$2.0b and US$6.4b is about US$6.7m. The CEO of SciPlay only received US$3.3m in total compensation for the year ending December 2022. That's clearly well below average, so at a glance that arrangement seems generous to shareholders and points to a modest remuneration culture. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. It can also be a sign of good governance, more generally. One important encouraging feature of SciPlay is that it is growing profits. To add to this, the modest CEO compensation should tell investors that the directors have an active interest in delivering the best for shareholders. So based on its merits, the stock deserves further research, if not an addition to your watchlist. While we've looked at the quality of the earnings, we haven't yet done any work to value the stock. So if you like to buy cheap, you may want to check if SciPlay is trading on a high P/E or a low P/E, relative to its industry. Shares of SciPlay Corp. rose after the company agreed to be acquired by Light & Wonder. There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features or you can count on our experts.
SLong
by moonypto